Search

Skip to main content Accessibility help

Home
Search

Only show content I have access to (0)

Chapters (1)

Last 3 years (1)

From year:

To year:

Apply

Medicine (1)

predictive drug development

Cambridge University Press (1)

View selected items
Save to my bookmarks
Export citations
Download PDF (zip)
Save to Kindle
Save to Dropbox
Save to Google Drive
Save content to
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to .

To save content items to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Please be advised that item(s) you selected are not available.
You are about to save
Your Kindle email address

Please provide your Kindle email.

@free.kindle.com @kindle.com (service fees apply)

By using this service, you agree that you will only keep content for personal use, and will not openly distribute them via Dropbox, Google Drive or other file sharing services

1 results

45 - National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias
from Section 7 - Funding and Financing Alzheimer’s Disease Drug Development
- By Laurie Ryan, Suzana Petanceska, Lorenzo Refolo
Edited by Jeffrey Cummings, University of Nevada, Las Vegas, Jefferson Kinney, University of Nevada, Las Vegas, Howard Fillit
Book:

Alzheimer's Disease Drug Development

Published online:

03 March 2022

Print publication:

31 March 2022, pp 503-512
- Chapter
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation
Summary

The National Institutes of Health (NIH) is the largest funder of Alzheimer’s disease and related demententias (AD/ADRD) research in the world. The National Institute on Aging (NIA), part of the NIH, leads the federal effort on AD/ADRD research. Since 2005 the NIA has been developing a robust translational research program for the treatment and prevention of AD dementia. In 2011, the National Alzheimer’s Project Act became law and ordered the creation of a National Plan to Address Alzheimer’s Disease. The National Plan was first released in 2012 and the first goal of the plan is to find effective ways to treat or prevent dementia by 2025. Since the first the release of the first National Plan in 2012, NIA’s funding for AD/ADRD research has steadily increased, allowing continued expansion and diversification of the drug development portfolio and the development of translational infrastructure programs to accelerate the discovery of effective therapies.

Search Results

Refine search

Refine search

Actions for selected content:

1 results

45 - National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias

Summary

Search Results

Refine search

Refine search

Actions for selected content:

Save Search

1 results

45 - National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias

Summary